861 RSV Hospitalization in Infants with Neuromuscular Disease in the Canadian Registry of Synagis® (Caress) Following Prophylaxis (2005–2011)

Background and Aims The Canadian Registry of Synagis® (CARESS) tracks palivizumab use and respiratory outcomes in high-risk infants, including those with neuromuscular impairments (NMI). We compared respiratory illness (RI) and respiratory syncytial virus positive hospitalization (RSVH) rates in NMI...

Full description

Saved in:
Bibliographic Details
Published in:Archives of disease in childhood 2012-10, Vol.97 (Suppl 2), p.A247-A247
Main Authors: Paes, B, Li, A, Mitchell, I, Lanctot, KL
Format: Article
Language:English
Subjects:
Body Weight
Infants
Prophylaxis
Young Children
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aims The Canadian Registry of Synagis® (CARESS) tracks palivizumab use and respiratory outcomes in high-risk infants, including those with neuromuscular impairments (NMI). We compared respiratory illness (RI) and respiratory syncytial virus positive hospitalization (RSVH) rates in NMI infants versus: 1) those with other underlying medical disorders (MD) and 2) those prophylaxed for standard indications (SD). Methods A prospective, observational registry of infants from 30 Canadian sites who received ≥1 dose of palivizumab during the 2005–2011 RSV seasons. Utilization and RI events were collected monthly throughout each season. Results 10452 infants were recruited (NMI: 118, 1.1%; MD: 1443, 13.8%; SD: 8891, 85.1%). There were statistically significant group differences (p5 individuals in the household, and history of atopy. NMI infants tended to have a less complex neonatal course. Compliance was similar across the three groups. The NMI group had higher RI hospitalization rates than MD or SD (17.8% versus 9.6% and 5.8%, p
ISSN:0003-9888
1468-2044
DOI:10.1136/archdischild-2012-302724.0861